AGC Biologics secures long-term manufacturing partnership with leading global biopharma
- AGC Biologics named long-term strategic manufacturing partner to a leading global biopharmaceutical company for multiple products.
- Total revenue under the agreement is expected to reach several tens of billions of yen over the contract term.
- The Yokohama Site will support mammalian cell-derived biologics, mRNA therapeutics and cell therapies, with one of Japan's largest mammalian cell culture capacities (AGC estimate).
- GMP-compliant services at the Yokohama Site are progressing toward launch in 2027, and will support global supply across Japan, the US and Europe.
Deal overview
AGC Biologics has entered a long-term manufacturing agreement with a leading global biopharmaceutical company and was selected as the customer's strategic manufacturing partner to support global supply of multiple biopharmaceutical products. Total revenue under the agreement is expected to reach several tens of billions of yen over the contract term.
Yokohama Site capabilities
The agreement will leverage AGC Biologics' new Yokohama Site, developed to support three modalities: mammalian cell-derived biologics, mRNA therapeutics and cell therapies. AGC estimates the site will offer one of the largest mammalian cell culture capacities among CDMO facilities in Japan, and commercial manufacturing services for the customer's products will utilize that capacity.
Timeline and network impact
AGC Biologics is progressing toward launching GMP-compliant services at the Yokohama Site in 2027. The site is intended to expand AGC Biologics' global network across Japan, the United States and Europe and contribute to the stable supply of biopharmaceutical products worldwide.
Source: AGC
